2019
463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)
Eu J, Yadav K, Lim Y, Hirpara J, Kong L, Ng Z, Lee V, Lee S, Tan D, Soo R, Chee C, Yong W, Sundar R, Lim J, Wang L, Ohi N, Tsunoda T, Pervaiz S, Goh B, Wong A. 463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC). Annals Of Oncology 2019, 30: v174. DOI: 10.1093/annonc/mdz244.025.Peer-Reviewed Original ResearchMitochondrial membrane potentialSerum metabolomeHER2+ breast cancerOncogene-addicted tumorsDose-finding phaseClinically tolerable dosesCancer stem cellsNon-significant riseG3/4 toxicitiesOxidative phosphorylation inhibitionSignificantly with treatmentGIST patientsTolerated doseTumor biopsiesImmunohistochemistry expressionCopy numberOxidative phosphorylationSerum lactateBreast cancerClinical developmentDrug resistanceMerck SeronoDose levelsDay 1Pathway inhibitor
2018
Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
Chan D, Syn N, Neogh C, Phua N, . E, Ho J, Sundar R, Tan C, Ngoi N, Chee C, Shabbir A, So J, Yong W. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2018, 36: 125-125. DOI: 10.1200/jco.2018.36.4_suppl.125.Peer-Reviewed Original ResearchConversion gastrectomyPeritoneal metastasisGastric cancerIP paclitaxelMedian OSPeritoneal cytologyDay 1Positive peritoneal washing cytologyTreated with 8 cyclesSurvival rateNegative peritoneal cytologyPeritoneal washing cytologyRecurrent gastric adenocarcinomaHand-foot syndromeMedian follow-upOverall survival rateWeek of restTime of reportingMedian no.Tumor perforationSystemic chemotherapyFebrile neutropeniaIncreasing drug concentrationPeritoneal diseasePeritoneal dissemination